ReviewFrontiers in neurology2019
Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Malignancy Risk and Predictors in Dermatomyositis and Polymyositis: A Large Population-Based Study.Medicina (Kaunas, Lithuania) · 2025Article
- Clinical Significance of Uncommon, Non-Clinical, and Novel Autoantibodies.ImmunoTargets and therapy · 2024Review
- Immune cell profiles of idiopathic inflammatory myopathy patients expressed anti-aminoacyl tRNA synthetase or anti-melanoma differentiation-associated gene 5 autoantibodies.BMC immunology · 2023Article
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- Review
- Article
- Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study.Biomedicines · 2023Article
- Coexistence of Multiple Myositis-Specific Antibodies in Patients with Idiopathic Inflammatory Myopathies.Journal of clinical medicine · 2022Article
- Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases.Current rheumatology reports · 2022Review
- The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker.International journal of molecular sciences · 2022Review
- Integrated analysis of plasma and urine reveals unique metabolomic profiles in idiopathic inflammatory myopathies subtypes.Journal of cachexia, sarcopenia and muscle · 2022Article
- Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.Immune network · 2022Review
- The Past, Present, and Future in Antinuclear Antibodies (ANA).Diagnostics (Basel, Switzerland) · 2022Review
- Review
- Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population.Frontiers in medicine · 2022Article
- Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies.Journal of translational autoimmunity · 2022Article
- Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021Review
- The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- NanoString technology distinguishes anti-TIF-1γBrain pathology (Zurich, Switzerland) · 2021Article
- Polishing the crystal ball: mining multi-omics data in dermatomyositis.Annals of translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic inflammatory myopathies represent still a diagnostic and therapeutic challenge in different disciplines including neurology, rheumatology, and dermatology. In recent years, the spectrum of idiopathic inflammatory myopathies has been significantly extended and the different manifestations were described in more detail leading to new classification criteria. A major breakthrough has also occurred with respect to new biomarkers especially with the characterization of new autoantibody-antigen systems, which can be separated in myositis specific antibodies and myositis associated antibodies. These markers are detectable in approximately 80% of patients and facilitate not only the diagnostic procedures, but provide also important information on stratification of patients with respect to organ involvement, risk of cancer and overall prognosis of disease. Therefore, it is not only of importance to know the significance of these markers and to be familiar with the optimal diagnostic tests, but also with potential limitations in detection. This article focuses mainly on antibodies which are specific for myositis providing an overview on the targeted antigens, the available detection procedures and clinical association. As major tasks for the near future, the need of an international standardization is discussed for detection methods of autoantibodies in idiopathic inflammatory myopathies. Furthermore, additional investigations are required to improve stratification of patients with idiopathic inflammatory myopathies according to their antibody profile with respect to response to different treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.